The Role of Cytokines in Acute and Chronic Postsurgical Pain in Pediatric Patients after

1

2 **Major Musculoskeletal Surgeries** 3 Vidya Chidambaran (MD)^a, Qing Duan (PhD)^b, Valentina Pilipenko (PhD)^b, Susan M. Glynn 4 (BA)^a, Alyssa Sproles (BA)^c, Lisa J. Martin (PhD)^d, Michael J. Lacagnina (PhD)^a, Christopher D. 5 King (PhD)^e, Lili Ding (PhD)^b 6 7 8 ^aDepartment of Anesthesiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 9 USA Vidya.Chidambaran@cchmc.org, Susan.Glynn@cchmc.org, Michael.Lacagnina@cchmc.org 10 11 12 ^bDivision of Biostatistics and Epidemiology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA Qing.Duan@cchmc.org 13 14 Valentia.Pilipenko@cchmc.org Lili.Ding@cchmc.org 15 16 ^cDivision of Rheumatology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA Alyssa.Sproles@cchmc.org 17 18 ^dDivision of Human Genetics, Department of Pediatrics, Cincinnati Children's Hospital Medical 19 Center, Cincinnati, OH, USA Lisa.Martin@cchmc.org 20 21 ^eDivision of Behavioral Medicine and Clinical Psychology, Department of Pediatrics, Cincinnati 22 Children's Hospital Medical Center, Cincinnati, OH, USA Christopher.King@cchmc.org 23 24 25 **Corresponding author:** Vidya Chidambaran, MD, MS 26 27 Professor, Department of Anesthesia, Cincinnati Children's Hospital Medical Center 28 3333 Burnet Avenue, Cincinnati, OH, 45229, USA 29 Email: vidya.chidambaran@cchmc.org, Phone: (513) 636-4408 30

- 31 **Running Title:** Cytokines in Chronic/Acute Pediatric Postsurgical Pain
- 32

1

33 Keywords: Cytokines, Pediatric, Acute postsurgical pain, chronic postsurgical pain

34

35 **Declarations of interest:** none

36

37 **Disclosures:** Research reported in this manuscript was supported by National Institute of

- 38 Arthritis and Musculoskeletal and Skin Diseases under award number 5R01AR075857
- 39 (PI:Chidambaran). The content is solely the responsibility of the authors and does not necessarily
- 40 represent the official views of the National Institutes of Health.
- 41
- 42
- 43

2

44 Abstract

45 **Study Objective:** To determine if baseline cytokines and their changes over postoperative days

- 46 0-2 (POD0-2) predict acute and chronic postsurgical pain (CPSP) after major surgery.
- 47 **Design:** Prospective, observational, longitudinal nested study.
- 48 **Setting:** University-affiliated quaternary children's hospital.
- 49 **Patients:** Subjects (≥8 years old) with idiopathic scoliosis undergoing spine fusion or pectus
- 50 excavatum undergoing Nuss procedure.

51 Measurements: Demographics, surgical, psychosocial measures, pain scores, and opioid use

52 over POD0-2 were collected. Cytokine concentrations were analyzed in serial blood samples

collected before and after (up to two weeks) surgery, using Luminex bead arrays. After data

54 preparation, relationships between pre- and post-surgical cytokine concentrations with acute (%

time in moderate-severe pain over POD0-2) and chronic (pain score>3/10 beyond 3 months post-

surgery) pain were analyzed. After adjusting for covariates, univariate/multivariate regression

analyses were conducted to associate baseline cytokine concentrations with postoperative pain,

and mixed effects models were used to associate longitudinal cytokine concentrations with pain

59 outcomes.

60 Main Results: Analyses included 3,164 measures of 16 cytokines from 112 subjects (median

age 15.3, IQR 13.5-17.0, 54.5% female, 59.8% pectus). Acute postsurgical pain was associated

62 with higher baseline concentrations of GM-CSF (β =0.95, SE 0.31; p=.003), IL-1 β (β =0.84, SE

63 0.36; p=.02), IL-2 ($\beta=0.78$, SE 0.34; p=.03), and IL-12 p70 ($\beta=0.88$, SE 0.40; p=.03) and

64 longitudinal postoperative elevations in GM-CSF (β =1.38, SE 0.57; *p*=.03), IFN γ (β =1.36, SE

65 0.6; p=.03), IL-1 β ($\beta=1.25$, SE 0.59; p=.03), IL-7 ($\beta=1.65$, SE 0.7, p=.02), and IL-12 p70

66 (β =1.17, SE 0.58; *p*=.04). In contrast, CPSP was associated with lower baseline concentration of

- 67 IL-8 (β = -0.39, SE 0.17; *p*=.02), and the risk of developing CPSP was elevated in patients with
- lower longitudinal postoperative concentrations of IL-6 (β = -0.57, SE 0.26; *p*=.03), IL-8 (β = -
- 69 0.68, SE 0.24; p=.006), and IL-13 ($\beta=-0.48$, SE 0.22; p=.03). Furthermore, higher odds for
- 70 CPSP were found for females (vs. males) for IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, and TNFα, and
- 71 for pectus (*vs.* spine) surgery for IL-8 and IL-10.
- 72 Conclusion: We identified pro-inflammatory cytokines associated with increased acute
- 73 postoperative pain and anti-inflammatory cytokines associated with lower CPSP risk, with
- 74 potential to serve as predictive and prognostic biomarkers.
- 75
- 76

4

77 **1. Introduction**

78

Major musculoskeletal surgeries are often accompanied by acute postsurgical pain, which 79 can have deleterious effects on long-term function and recovery, leading to chronic postsurgical 80 81 pain (CPSP). Pectus excavatum repair and spine deformity correction surgery are two such painful surgeries adolescents undergo and are associated with extensive dissection, muscle 82 derangements, inflammation, nerve sensitization [1] and CPSP [2, 3]. Surgeries are often 83 84 associated with a host of immune responses following tissue injury and incision [4]. These 85 include the release of cytokines, stress responses and acute phase proteins, which can be harmful 86 when excessive. [5] At the same time, these responses are the body's defense against infection 87 and tissue damage, and their release can be protective. Thus, a simple anti-inflammatory strategy 88 for example with Non-steroidal Anti-inflammatory Drugs raises concerns regarding adverse 89 effects, such as infection and delayed wound-healing[6]. Understanding how these inflammatory 90 responses impact pain outcomes is therefore important to know which cytokines may promote 91 healing and which ones are associated with harmful pain. 92 Cytokines, as pivotal regulators of immune and inflammatory processes, have emerged as key players in the modulation of pain pathways.[7] Cytokines are soluble molecular substances 93 produced by inflammatory cells. Broadly, they can be either pro-inflammatory (e.g., interleukins 94 95 (IL)-1, 2, 8, 12; tumor necrosis factor α (TNF α), interferon γ (IFN γ)) or anti-inflammatory (e.g. IL-4, IL-10, IL-13, transforming growth factor beta (TGF β)), while some such as IL-6 can be 96 97 both pro- and anti-inflammatory. Pro-inflammatory cytokines may be associated with 98 postoperative pain after musculoskeletal surgeries [8] and may activate neural circuits to

99 maintain hyperalgesia states [9]. Certain inflammatory profiles in the serum and body fluids have

been suggested to be characteristic of poorly resolving pain after joint surgery [10]. However,

101	other studies have refuted these findings and did not find associations between perioperative
102	cytokine concentrations with postoperative pain following total knee arthroplasty [11]. Thus,
103	there is a lack of understanding of the role of cytokines in acute and chronic postoperative pain.
104	This is crucial for developing targeted and effective pain management strategies, as a precise
105	understanding of the cytokine response to surgical trauma may inform interventions that would
106	optimize perioperative care, decrease morbidity and enhance recovery.
107	In this study, we aimed to investigate whether baseline cytokine profiles and longitudinal
108	concentration changes in cytokines after surgery predicted acute and chronic postoperative pain
108 109	concentration changes in cytokines after surgery predicted acute and chronic postoperative pain outcomes. We hypothesized pro-inflammatory cytokines such as interferon gamma interferon
109	outcomes. We hypothesized pro-inflammatory cytokines such as interferon gamma interferon

6

113 **2. Materials and Methods**

114 This prospective, observational, longitudinal study was nested within a larger genomics study (ClinicalTrials.gov Identifier: NCT02998138, NCT01839461, NCT01731873) and was 115 116 conducted at a university-affiliated quaternary children's hospital. The Cincinnati Children's Institutional Review Board approved the study. Results pertaining to psychosocial factors and 117 epigenetic factors influencing CPSP have been previously published [3, 12, 13]. Written 118 119 informed consent was obtained from parents and assent from children before enrollment, either on paper or electronically, through Research Electronic Data Capture (REDCap), a secure web 120 121 application for building and managing online surveys and databases. This study adhered to the Reporting of Observational Studies in Epidemiology (STROBE) guidelines [14]. 122 123 124 2.1 Participants Healthy children aged 8 years and above, regardless of sex or race, were included if they 125 126 had a diagnosis of idiopathic scoliosis/kyphosis or pectus excavatum, American Society of 127 Anesthesiologists physical status ≤ 2 (mild systemic disease) and were scheduled for elective spine fusion or Nuss procedure. They were screened from operating room schedules and 128 129 recruited if they satisfied inclusion/exclusion criteria. Exclusion criteria included a history of opioid use in the past six months, liver and renal disease, pregnant or breastfeeding females, 130 developmental delay, cancer, and those not fluent in written and/or spoken English. Perioperative 131 management included standardized surgery-specific anesthesia and multimodal pain protocols. 132 133 Patients undergoing either surgery received acetaminophen and ketorolac (on postoperative day (POD)0-2), dexamethasone (intraoperative only), muscle relaxants and opioids. Pectus patients 134 135 also received regional anesthesia, methadone and pregabalin.

7

136 2.2 Data collection

137	Data were collected by chart review and via questionnaires administered through
138	REDCap via email. Before surgery, the following data were collected: demographics (sex, age,
139	race), weight, pain scores (numerical rating scale (NRS) 0-10)[15], diagnosis and surgery type.
140	The Pediatric Pain Screening Tool (PPST) was administered preoperatively – a brief, 9-item self-
141	report questionnaire developed for rapid identification of risk for poor pain coping. It has been
142	validated in patients with chronic pain and within this surgical cohort for CPSP risk stratification
143	[12, 16]. The first four items evaluate physical symptoms, and the next four questions evaluate
144	psychosocial constructs. PPST total scores range from 0 to 9. Perioperative data collected
145	included duration of surgery, pain scores (recorded every four hours) and analgesia (opioid
146	medications/doses, (intravenous, oral and patient-controlled analgesia) over 48 hours after
147	surgery. After hospital discharge, questionnaires were administered via REDCap 3-6 and 10-12
148	months after surgery to obtain pain measures (average and maximum pain scores over the last
149	week).

150

151 2.2.1 Blood draws

Blood was collected from intravenous catheters placed for clinical purposes and /or indwelling lines. An 8 ml sample was collected in purple top/EDTA tubes at baseline. Additional samples (1-2 ml) were collected at the scheduled time-points (**Figure 1**). The total amount of blood drawn per patient was approximately 30 ml. Whole blood samples were centrifuged at 3500 rpm for 10 minutes, plasma aliquoted into two tubes (minimal volume per freezer aliquot tube: 250 microliters) and stored at -80°C until analysis.

8

158 2.2.2 Postoperative pain outcomes

159	Acute postsurgical pain was defined as a log-transformed compositional outcome of %
160	time spent in moderate – severe pain (NRS>3/10) over POD0-2. Based on area under curve for
161	repeat pain scores measured over POD0-2, % time for which pain scores were>3/10 was
162	calculated. Log-ratio transformation was applied as defined as: f= log (average of % time spent
163	in moderate or severe pain over POD0-2/ average of % time spent in mild pain over POD0-2).
164	
165	CPSP was defined as any pain (NRS>3/10) beyond 3 months post-surgery. NRS cut-offs
166	of 3/10 depict moderate/severe pain, are associated with functional disability, and have been
167	described as a predictor for the persistence of pain [17].
168	
169	2.3 Cytokine analyses
170	Cytokine levels were assayed using the Luminex multiplex (Milliplex) immunoassay
171	bead array technology. Kits from R&D Systems (LXSAHM-12) analyzed chemokine CCL22,
172	epidermal growth factor (EGF), fractalkine, IFNy, IL-1 receptor antagonist (IL-1ra), IL-2, IL-4,
173	IL-6, IL-8, IL-10, IL-13, and TNFα levels; and Millipore Sigma (HSTCMAG28PMX13BK)
174	analyzed granulocyte-macrophage colony-stimulating factor (GM-CSF), IFNy, IL-1β, IL-2, IL-4,
175	IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p70), IL-13 and TNF α levels and run according to the
176	manufacturer's protocol. See supplemental figures for sensitivity and precision. Concentrations
177	were calculated from standard curves using recombinant proteins and expressed in pg/ml using
178	Bio-Plex Manager 6.2 (Bio-Rad Laboratories, Hercules, CA).

179

9

180 2.4 Statistical analyses

Fluorescence intensities were transferred into R (http:www.r-project.org) statistical software for converting into concentration values. Cytokine concentrations were determined from the standard serial dilutions, and standard curves were obtained from the Bayesian hierarchical 5-parameter logistic models created in the R package nCal [18]. Data cleaning and preparation for cytokine data included several steps (weighting, normality check and log transformation, winsorization, ComBat in R package sva for batch effect adjustment and handling of duplicates).

188 To test if baseline cytokines was associated with acute pain or CPSP, we first conducted an unadjusted analysis to determine if baseline cytokines were associated with acute pain and 189 compared values between CPSP groups using t-tests (Pooled or Satterthwaite based on the test of 190 191 equality of variances). We assessed the influence of covariates (age, biological sex, race, PPST, surgical duration, surgery type and morphine equivalents per kg (MEQ) or confounders 192 (associated with both the independent variables and the outcomes). We then conducted multiple 193 194 linear or logistic regression for the log-ratio transformed acute pain and CPSP outcomes, respectively, after eliminating collinear variables, and adjusting for covariates or confounders. 195 196 For testing if longitudinal cytokine concentration changes with time were associated with pain outcomes, we computed cytokine AUC for POD0, 1 and 2 (using cytokine concentration 197 and time approximations based on blood draw timings), where cytokine AUC for POD0 was 198 199 standardized to 24 hours. Cytokine AUCs were log-transformed before analysis. To evaluate the 200 effect of changes in cytokine on acute pain outcome, mixed effects models with the acute pain as the dependent and log transformed cytokine AUC on POD0-2 as the independent variables were 201 202 used. To evaluate the association between cytokine and CPSP, mixed effects models with log-

203 1	transformed cytokine AUC	on POD0-2 as the	outcome and binary	CPSP as the independent
-------	--------------------------	------------------	--------------------	-------------------------

- variable were used. POD, sex, race, surgical duration, surgery type, and total MEQ were
- 205 included as covariates and subjected to a random effect. We assessed for collinearity (or extreme
- 206 confounding) for those variables associated with the outcomes based on tolerance, variance
- 207 inflation factor (VIF) or generalized variance inflation factor (GVIF) for categorical variables.
- 208 We eliminated correlated variables in both multiple regression and mixed effects models. Results
- from full models (supplementary material) and reduced models, where only covariates with $p \le 1$
- 210 0.05 were retained, are presented.

11

211 **3. Results**

212	In all, 112 subjects were included in the study. Patient, surgical and outcome summary
213	statistics are provided in Table 1. The majority of subjects were White (97.3%) and female
214	(54.5%) and underwent pectus or spine surgeries under standardized anesthesia/pain protocols.
215	The incidence of CPSP in this cohort was 43.9%, with loss of retention in five subjects. One of
216	the cytokines, EGF, was excluded from the regression analysis because the reported
217	concentrations had the same value across all time points.
218	
219	A total of 4230 cytokine concentration measures were initially included in the analyses.
220	After data cleaning, the resulting number of observations was 3334. Details of data cleaning,
221	tables of winsorized data, plots of before and after ComBat adjustment (Supplementary Fig 1)
222	and cytokine data by CPSP over regrouped time points (Supplementary Fig 2) are presented in
223	the supplementary materials. Finally, n=3249 concentrations from subjects who self-identified as
224	belonging to White and Black race were included for association analyses due to the small
225	number of subjects from other races.
226	
227	3.1 Univariate associations between baseline cytokines with postoperative pain outcomes
228	Using unadjusted model, a series of simple linear regressions showed higher acute pain
229	associated with GM-CSF (β =0.90, SE 0.33, <i>p</i> =.008), IL-2 (β =0.79, SE 0.35, <i>p</i> =.03), and IL-12
230	p70 (β =0.92, SE 0.43, <i>p</i> =.04) concentrations at baseline (Table S1). Comparison of baseline
231	cytokines between CPSP and controls showed differences only for CCL22 (CPSP 5.90±0.52
232	pg/ml vs. control 6.51 \pm 0.40); p=.004) (Table S2).
233	

12

3.2 Multivariate adjusted analyses: Baseline cytokines and pain outcomes

235 Biological sex, and surgery type were associated with CPSP, while MEQ was associated 236 with acute pain outcomes (p < .05). Participant's sex was also associated with IL-2 and MEQ with 237 IL-8 levels (acted as confounders). Thus, in models adjusted for sex, MEQ, and surgery type, a series of analyses were conducted to evaluate the association of baseline cytokines with CPSP 238 and acute pain (Table S3). Baseline cytokine concentrations were associated with acute pain for 239 240 GM-CSF (β =0.95, SE 0.31; p=.003), IL-1 β (β =0.84, SE 0.36; p=.02), IL-2 (β =0.78, SE 0.34; 241 p=.03), and IL-12 p70 ($\beta=0.88$, SE 0.40; p=.03), after controlling for relevant covariates and confounders (Table 2). In general, greater cytokine concentration levels were associated with 242 with higher MEQ (p<.001). After controlling for relevant covariates and confounders, baseline 243 cytokine concentrations were associated with CPSP for IL-8 (β = -0.39, SE 0.17; p=.02) (**Table** 244 245 3). Baseline concentrations were associated with increased odds for CPSP in female (vs. male) 246 sex (IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, and TNFα) and pectus (vs. spine) surgery patients (IL-8, IL-10). 247

248

3.2 Mixed effects model: Association of cytokine concentrations over time with acute pain outcome

Mixed effects models were also adjusted for surgical duration/type, MEQ, sex, and race. In the full model, log cytokine AUC was associated with acute pain in GM-CSF (β =1.38, SE 0.57; *p*=.03), IFN γ (β =1.36, SE 0.6; *p*=.03), IL-1 β (β =1.25, SE 0.59; *p*=.03), IL-7 (β =1.65, SE 0.7; *p*=.02), and IL-12 p70 (β =1.17, SE 0.58; *p*=.04) (**Table 4**). POD, surgery type/duration and MEQ were adjusted in several cytokine-acute pain association models (**Table S4**). The final reduced multiple regression model revealed associations with GM-CSF, IFN γ , IL-1 β , IL-5, IL-7,

257	and IL-12 p70 (p<.05) after adjusting for surgical duration (Table 4). Estimates for an
258	association of covariates were positive except for POD2, indicating decreasing acute pain over
259	POD2.
260	
261	3.4 Mixed effects model: Association of longitudinal cytokine concentrations and CPSP
262	
263	Line chart of cytokine concentrations over time are provided in Fig S2, and the full
264	model is in Table S5 . CPSP was significantly associated with log cytokine AUC for IL-6 (β = -
265	0.57, SE 0.26; <i>p</i> =.03), IL-8 (β = -0.68, SE 0.24; <i>p</i> =.006), and IL-13 (β = -0.48, SE 0.22; <i>p</i> =.03)
266	(Table 4). Postoperative day and surgical duration were adjusted in the reduced model. Estimates
267	for association with log cytokine AUC were negative for pectus surgery and Black race and
268	positive for POD (POD1 and POD2) and MEQ. (Table S5)

14

269 **4. Discussion**

270	In this prospective study of adolescents undergoing pectus or spine deformity correction
271	surgery, cytokines were assayed from blood samples collected preoperatively and over six time
272	points over POD0-2 and week 2 after surgery. The aims were to determine associations of
273	baseline and longitudinal cytokine changes over POD0-2 with acute and chronic postoperative
274	pain, adjusted for other covariates. We identified POD, sex, MEQ and surgery type/duration as
275	covariates, as these were associated with cytokine and pain outcomes. Multivariate regression
276	models revealed that higher baseline (i.e., preoperative) levels of GM-CSF, IL-1 β , IL-2, and IL-
277	12 p70 concentrations were associated with acute pain (i.e., % time in moderate-severe pain after
278	surgery) while higher levels of baseline IL-8 decreased the odds for CPSP. Mixed effects models
279	demonstrated that longitudinal postoperative cytokine concentrations of IL-6, IL-8, and IL-13
280	were protective for CPSP (i.e. increased concentration decreased odds of developing CPSP),
281	while higher longitudinal postoperative concentrations of GM-CSF, IFN γ , IL-1 β , IL-7, and IL-12
282	p70 were associated with higher acute pain. Collectively, our data identified distinct cytokine
283	signatures that are associated with differential outcomes for acute and chronic postsurgical pain.
284	Severity of acute pain was predicted by elevations of mostly pro-inflammatory, chemotactic, and
285	proliferative cytokines, while likelihood of developing chronic pain was associated with baseline
286	and postoperative elevations of IL-6, IL-8, and IL-13, which suggest a pain-resolving mechanism
287	associated with these immune mediators.

The immediate postoperative period is characterized by an orchestrated release of
cytokines in response to surgical trauma. We found that baseline or overall AUC of GM-CSF,
IFNγ, IL-1β, IL-2, IL-7, and IL-12 p70 were higher with % time in moderate-severe pain on
POD0-2. Several of these cytokines are known to be pro-inflammatory; some are secreted by T

15

292	helper cells and lead to the growth/differentiation of monocytes (GM-CSF) and proliferation of B
293	cells, T cells, and natural killer (NK) cells (IL-2, IL-7). In contrast, others are released by
294	macrophages and act on NK cells (IL-12 p70) and lead to IFN γ release, which activates
295	macrophages, neutrophils and NK cells and promotes cell-mediated immunity. IL-6 and TNF α
296	have also been implicated in sensitizing pain pathways and amplifying nociceptive signals[7].
297	However, our study did not find them to be associated with pain outcomes. This aligns with other
298	studies in adults. After hip arthroplasty serial IL-6 concentrations on POD1 were found to predict
299	disability but not pain on discharge [19]., or long-term disability at one and six months after
300	surgery. Another study evaluating preoperative IL-6 and $TNF\alpha$ did not predict early pain or
301	function after total hip arthroplasty [20]. These conflicting reports suggest that individual
302	cytokine concentrations are not uniformly predictive of pain outcomes, and further work is
303	required to uncover specific determinants of inflammatory responses in the postoperative period.
304	Traditionally, cytokines such as IL-1 receptor antagonist, IL-4, IL-10, IL-11, and IL-13
305	are considered anti-inflammatory. Low blood levels of IL-4 and IL-10 were reported to be
306	associated with chronic widespread pain [21]. However, we did not find associations between IL-
307	4 or IL-10 with CPSP. We did find IL-13 to be protective for CPSP. IL-13 (and IL-4) belong to
308	the T helper 2 (Th2) cytokine family and have been shown to play a role in downmodulating
309	inflammatory responses in rheumatoid arthritis, induce macrophage polarization from a pro-
310	inflammatory M1 to an anti-inflammatory M2 phenotype [22]. Studies in mice have shown that
311	IL-13 released from T cells can polarize macrophages into an M2-like phenotype, and the
312	resulting production of anti-inflammatory cytokines from these polarized macrophages was
313	found to be critical for the resolution of chemotherapy-induced peripheral neuropathy.[23]. IL-13
314	signaling uses the JAK-signal transducer and activator of the transcription (STAT) pathway,

16

315	specifically STAT6 [24], and these pathways may be future intervention targets. We also found
316	baseline IL-8 and postoperative IL-8 AUC over POD0-2 to be protective for CPSP. However,
317	this is not aligned with its known pro-inflammatory role and its association with pain in other
318	studies [25]. Instead, our data support the notion that IL-8 may promote the recruitment or
319	expansion of endogenous pain-resolving immune cells [add citations]. In support of this, patients
320	with transcriptional responses associated with acute neutrophil activation after injury were less
321	likely to transition from acute to chronic lower back pain[26]. Furthermore, female sex remained
322	a significant factor associated with higher CPSP in these models. Our findings are aligned with
323	those of a study of inflammatory markers in chronic pelvic pain patients. They reported IL-8 was
324	protective with a sex-specific effect: women with pelvic pain showed a negative relationship
325	between IL-8 and widespread pain, while men did not [27]. Female sex was also a covariate for
326	AUC cytokine associations with CPSP for IL-4, IL-6, IL-8, and IL-13 cytokines. In an
327	experimental study of sex effects on lipopolysaccharide (LPS) induced immune activation,
328	visceral and musculoskeletal hyperalgesia was found to occur in both men and women,
329	irrespective of biological sex. However, the LPS-induced cytokine increases in women were
330	more pronounced [28]. Thus, future studies should investigate sex-cytokine interactions in pain
331	as a biological mechanism for sex differences in pain.

332

We identified postsurgical time-dependent changes in cytokine levels with increased
cytokine levels on POD1 followed by a decline on POD2. This is similar to the results of another
study in 11 patients which found that five cytokines (IL-4, IL-6, IL-10, IL-12 p70 and IL-13) in
plasma and ten cytokines in the cerebrospinal fluid (CSF) (IFNγ, IL-1β, IL-2, IL-4, IL-6, IL-8,
IL-10, IL-12 p70, IL-13, and TNFα) rose significantly following femoral neck surgery [29].

17

However, the study did not report associations with clinical pain. Interestingly,
neuroinflammatory responses (in CSF) were not shown to correlate with plasma levels. This is
surprising as postsurgical studies in elderly patients found plasma TNFα, IL-6, and IL-10 levels
to be independent predictors for adverse central postoperative outcomes such as cognitive
deficits [30]. Future studies need to understand better the correlation of neuroinflammatory
markers in clinical pain cohorts.

Surgery type (pectus vs spine) was associated with IL-8 and IL-10 at baseline in CPSP
and acute pain association models. Prior research has shown similar differences with IL-6
increases with more major surgery (aortic vs. hernia surgery) and in those with complications
(N=3) [31] Opioid consumption was identified as a covariate for the association of baseline
cytokine as well as cytokine exposure (AUC) for several cytokines (GM-CSF, IL-1β, IL2-8, IL10, IL-12 p70, IL-13, TNFα) with acute pain, even when surgery type and duration were adjusted
for in the models.

351

352 Our findings support the hypothesis that pro-inflammatory antagonists or anti-353 inflammatory agents could attenuate acute and chronic postsurgical pain. Our results predict that 354 pharmacological or immunomodulatory approaches to broadly inhibit circulating pro-355 inflammatory cytokines would improve outcomes associated with acute pain, while interventions 356 to elevate IL-6, IL-8, and IL-13 in the immediate postoperative period could prevent the 357 transition from acute to chronic pain. Although it remains an ongoing challenge to suppress painpromoting inflammation while promoting pain-resolving immune responses, there is evidence 358 359 that immunotherapies may improve the treatment of ongoing pain[32, 33]. For example, anti-360 TNF α agents such as etanercept have found promise in inflammatory conditions such as

18

361	rheumatoid arthritis [34]. Recently, IL-13 administration in mice was found to reverse
362	inflammatory macrophage-dependent neuropathic pain via a phenotype shift toward suppressive
363	macrophages [35]. Our results add to the evolving understanding of cytokine involvement in
364	postoperative pain, supporting emerging strategies targeting cytokine signaling to alleviate
365	postoperative pain in children. Of note, multimodal analgesia components such as intravenous
366	lidocaine and dexamethasone have been investigated for their anti-inflammatory effects and
367	potential analgesic benefits after major musculoskeletal surgeries such as spine fusion, with
368	mixed evidence regarding their benefits [36, 37].
369	
370	4.1 Limitations
371	One limitation of our study is that we did not adjust statistical significance for multiple
372	tests. Despite this, to our knowledge, this might be the first study of longitudinal cytokines in
373	relation to acute and chronic post-surgical pain in a well characterized, prospective, pediatric
374	cohort. Moreover, the generalization over two surgeries makes our findings generalizable. Also,
375	although the data was analyzed in different batches, we used high rigor in normalizing and
376	analyzing the cytokine data. Despite the study's observational nature, spine and pectus surgical

patients received standardized protocols, minimizing differences in pain management regimens.

378

379 4.2 Conclusions

In conclusion, this paper describes the association between cytokines and acute and
chronic postoperative pain in pediatric patients. Cytokine measurements perioperatively may not
only serve as biomarkers and enable prediction of pain-related risk but also suggest potential

19

- tailored interventions, thus paving the way for more personalized and effective pain management
- in the pediatric surgical setting. Future studies need to elucidate sex interactions with immune
- 385 signaling and surgery-specific differences.

386

387 Acknowledgments

- 388 The authors gratefully acknowledge Maria E Ashton, MS, RPh, MBA, Medical Writer,
- 389 Department of Anesthesiology, Cincinnati Children's Hospital Medical Center, for providing
- 390 writing assistance, editing, and proofreading.

20

391 **References**

- 392 [1] Lee CS, Merchant S, Chidambaran V. Postoperative Pain Management in Pediatric Spinal Fusion
- 393 Surgery for Idiopathic Scoliosis. Paediatr Drugs. 2020;22:575-601.
- 394 [2] Rabbitts JA, Fisher E, Rosenbloom BN, Palermo TM. Prevalence and Predictors of Chronic Postsurgical
- Pain in Children: A Systematic Review and Meta-Analysis. J Pain. 2017;18:605-14.
- [3] Chidambaran V, Ding L, Moore DL, Spruance K, Cudilo EM, Pilipenko V, et al. Predicting the pain
- continuum after adolescent idiopathic scoliosis surgery: A prospective cohort study. Eur J Pain.
 2017;21:1252-65.
- 399 [4] Weledji EP. The role of cytokines in enhanced recovery after surgery. IJS Short Reports. 2021;6.
- 400 [5] Hsing C-H, Wang J-J. Clinical implication of perioperative inflammatory cytokine alteration. Acta
 401 Anaesthesiologica Taiwanica. 2015;53:23-8.
- 402 [6] Bosch DJ, Nieuwenhuijs-Moeke GJ, van Meurs M, Abdulahad WH, Struys M. Immune Modulatory
- 403 Effects of Nonsteroidal Anti-inflammatory Drugs in the Perioperative Period and Their Consequence on
- 404 Postoperative Outcome. Anesthesiology. 2022;136:843-60.
- 405 [7] Grace PM, Hutchinson MR, Maier SF, Watkins LR. Pathological pain and the neuroimmune interface.
 406 Nat Rev Immunol. 2014;14:217-31.
- 407 [8] Si HB, Yang TM, Zeng Y, Zhou ZK, Pei FX, Lu YR, et al. Correlations between inflammatory cytokines,
- 408 muscle damage markers and acute postoperative pain following primary total knee arthroplasty. BMC
 409 Musculoskelet Disord. 2017;18:265.
- 410 [9] Watkins LR, Maier SF, Goehler LE. Immune activation: the role of pro-inflammatory cytokines in
- 411 inflammation, illness responses and pathological pain states. Pain. 1995;63:289-302.
- 412 [10] Gandhi R, Santone D, Takahashi M, Dessouki O, Mahomed NN. Inflammatory predictors of ongoing
- 413 pain 2 years following knee replacement surgery. Knee. 2013;20:316-8.
- 414 [11] Azim S, Nicholson J, Rebecchi MJ, Galbavy W, Feng T, Rizwan S, et al. Interleukin-6 and leptin levels
- 415 are associated with preoperative pain severity in patients with osteoarthritis but not with acute pain
- 416 after total knee arthroplasty. Knee. 2018;25:25-33.
- 417 [12] Narayanasamy S, Yang F, Ding L, Geisler K, Glynn S, Ganesh A, et al. Pediatric Pain Screening Tool: A
- 418 Simple 9-Item Questionnaire Predicts Functional and Chronic Postsurgical Pain Outcomes After Major
- 419 Musculoskeletal Surgeries. J Pain. 2022;23:98-111.
- 420 [13] Chidambaran V, Zhang X, Geisler K, Stubbeman BL, Chen X, Weirauch MT, et al. Enrichment of
- 421 Genomic Pathways Based on Differential DNA Methylation Associated With Chronic Postsurgical Pain and
 422 Anxiety in Children: A Prospective, Pilot Study. J Pain. 2019;20:771-85.
- 423 [14] Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening
- 424 the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration.
- 425 Epidemiology. 2007;18:805-35.
- 426 [15] von Baeyer CL. Numerical rating scale for self-report of pain intensity in children and adolescents:
- 427 recent progress and further questions. Eur J Pain. 2009;13:1005-7.
- 428 [16] Simons LE, Smith A, Ibagon C, Coakley R, Logan DE, Schechter N, et al. Pediatric Pain Screening Tool:
 429 rapid identification of risk in youth with pain complaints. Pain. 2015;156:1511-8.
- 430 [17] Gerbershagen HJ, Rothaug J, Kalkman CJ, Meissner W. Determination of moderate-to-severe
- 431 postoperative pain on the numeric rating scale: a cut-off point analysis applying four different methods.
- 432 Br J Anaesth. 2011;107:619-26.
- 433 [18] Fong Y, Sebestyen K, Yu X, Gilbert P, Self S. nCal: an R package for non-linear calibration.
- 434 Bioinformatics. 2013;29:2653-4.
- 435 [19] Hall GM, Peerbhoy D, Shenkin A, Parker CJ, Salmon P. Relationship of the functional recovery after
- hip arthroplasty to the neuroendocrine and inflammatory responses. Br J Anaesth. 2001;87:537-42.

- 437 [20] Poehling-Monaghan KL, Taunton MJ, Kamath AF, Trousdale RT, Sierra RJ, Pagnano MW. No
- 438 Correlation Between Serum Markers and Early Functional Outcome After Contemporary THA. Clin 439
- Orthop Relat Res. 2017;475:452-62.
- 440 [21] Uceyler N, Valenza R, Stock M, Schedel R, Sprotte G, Sommer C. Reduced levels of antiinflammatory
- 441 cytokines in patients with chronic widespread pain. Arthritis Rheum. 2006;54:2656-64.
- 442 [22] Iwaszko M, Biały S, Bogunia-Kubik K. Significance of Interleukin (IL)-4 and IL-13 in Inflammatory
- 443 Arthritis. Cells. 2021;10.
- 444 [23] Singh SK, Krukowski K, Laumet GO, Weis D, Alexander JF, Heijnen CJ, et al. CD8+ T cell-derived IL-13 445 increases macrophage IL-10 to resolve neuropathic pain. JCI Insight. 2022;7.
- 446 [24] Takeda K, Kamanaka M, Tanaka T, Kishimoto T, Akira S. Impaired IL-13-mediated functions of
- 447 macrophages in STAT6-deficient mice. J Immunol. 1996;157:3220-2.
- 448 [25] Hedderson WC, Borsa PA, Fillingim RB, Coombes SA, Hass CJ, George SZ. Plasma Concentrations of
- 449 Select Inflammatory Cytokines Predicts Pain Intensity 48 Hours Post-Shoulder Muscle Injury. Clin J Pain. 450 2020;36:775-81.
- 451 [26] Parisien M, Lima LV, Dagostino C, El-Hachem N, Drury GL, Grant AV, et al. Acute inflammatory
- 452 response via neutrophil activation protects against the development of chronic pain. Sci Transl Med. 453 2022;14:eabj9954.
- 454 [27] Karshikoff B, Martucci KT, Mackey S. Relationship Between Blood Cytokine Levels, Psychological
- 455 Comorbidity, and Widespreadness of Pain in Chronic Pelvic Pain. Frontiers in Psychiatry. 2021;12.
- 456 [28] Wegner A, Elsenbruch S, Rebernik L, Roderigo T, Engelbrecht E, Jäger M, et al. Inflammation-induced
- 457 pain sensitization in men and women: does sex matter in experimental endotoxemia? Pain.
- 458 2015;156:1954-64.
- 459 [29] Fertleman M, Pereira C, Dani M, Harris BHL, Di Giovannantonio M, Taylor-Robinson SD. Cytokine
- 460 changes in cerebrospinal fluid and plasma after emergency orthopaedic surgery. Scientific Reports. 461 2022;12:2221.
- 462 [30] Sun T, Wang X, Liu Z, Chen X, Zhang J. Plasma concentrations of pro- and anti-inflammatory
- 463 cytokines and outcome prediction in elderly hip fracture patients. Injury. 2011;42:707-13.
- 464 [31] Baigrie RJ, Lamont PM, Kwiatkowski D, Dallman MJ, Morris PJ. Systemic cytokine response after
- 465 major surgery. Br J Surg. 1992;79:757-60.
- 466 [32] Kavelaars A, Heijnen CJ. Immune regulation of pain: Friend and foe. Sci Transl Med.

467 2021;13:eabj7152.

- 468 [33] Fiore NT, Debs SR, Hayes JP, Duffy SS, Moalem-Taylor G. Pain-resolving immune mechanisms in 469 neuropathic pain. Nat Rev Neurol. 2023;19:199-220.
- 470 [34] Hung AL, Lim M, Doshi TL. Targeting cytokines for treatment of neuropathic pain. Scandinavian
- 471 Journal of Pain. 2017;17:287-93.
- 472 [35] Kiguchi N, Sakaguchi H, Kadowaki Y, Saika F, Fukazawa Y, Matsuzaki S, et al. Peripheral administration
- 473 of interleukin-13 reverses inflammatory macrophage and tactile allodynia in mice with partial sciatic
- 474 nerve ligation. Journal of Pharmacological Sciences. 2017;133:53-6.
- 475 [36] Dewinter G, Moens P, Fieuws S, Vanaudenaerde B, Van de Velde M, Rex S. Systemic lidocaine fails to
- 476 improve postoperative morphine consumption, postoperative recovery and quality of life in patients
- 477 undergoing posterior spinal arthrodesis. A double-blind, randomized, placebo-controlled trial. British 478 Journal of Anaesthesia. 2017;118:576-85.
- 479 [37] Farag E, Ghobrial M, Sessler DI, Dalton JE, Liu J, Lee JH, et al. Effect of Perioperative Intravenous
- 480 Lidocaine Administration on Pain, Opioid Consumption, and Quality of Life after Complex Spine Surgery.
- 481 Anesthesiology. 2013;119:932-40.
- 482

22

483 Figure legends

484	Figure 1:	Timeline	of blood	draws i	in relation	to surgery	(marked	by recta	angle of	different	shade).
-----	-----------	----------	----------	---------	-------------	------------	---------	----------	----------	-----------	---------

- 485 Samples are named alphabetically and sequentially. Some samples were combined and averaged
- based on time of draw (BC and DE). * indicates they were drawn only for spine surgery subjects.
- 487 # indicates they were drawn only for pectus surgery subjects, due to differences in protocols and
- to gather more samples. POD: Postoperative day; PACU: Postoperative care unit.

489			
490			
491			
492			
493			
494			
495			
496			
497			
498			
499			
500			

502	Table 1:	Characteristics of s	tudy participants	(n=112) and variables
-----	----------	----------------------	-------------------	-----------------------

503

Variable	Category	Mean (SD) or Median (IQR) (n=112)	Min, Max	Missing (%)
Age	Cutegory	15.3 (13.5, 17.0) [n=112]	9.2, 36.4	0 (0.0)
Sex	Female	61 (54.5)	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	0 (0.0)
	Male	51 (45.5)		- ()
Race	Black	3 (2.7)		0 (0.0)
	White	109 (97.3)		
Surgical duration (minutes)		147.5 (90.5, 224.0) [n=112]	58.0, 383.0	0 (0.0)
Surgery	pectus	67 (59.8)		0 (0.0)
	spine	45 (40.2)		
PPST		1.0 (0.0, 3.0) [n=77]	0.0, 9.0	35 (31.3)
MEQ POD0-2		1.0 (0.7, 1.4) [n=112]	0.1, 4.1	0 (0.0)
CPSP	No	60 (56.1)		5 (4.5)
	Yes	47 (43.9)		
Acute pain POD0-2		0.1 (-0.9, 1.2) [n=104]	-8.5, 8.5	8 (7.1)

24

- 523 Table 2: Regression analysis of cytokine log concentration levels at baseline and acute pain (log
- transformed pain AUC over POD0-1)

Cytokine	Parameter with Relevant Covariates	Estimate	StdErr	<i>p</i> -value
CCL22	Log concentration	-1.65	1.33	0.225
Fractalkine	Log concentration <i>Covariate</i> : Race (Black vs. White)	-1.89 2.69	2.30 4.11	0.419 0.519
GM-CSF	Log concentration <i>Covariate</i> : MEQ, POD0-2	0.95 1.67	0.31 0.41	<mark>0.003</mark> <.001
IFNγ	Log concentration <i>Covariate</i> : MEQ, POD0-2	0.43 1.43	0.43 0.40	0.315 < 0.001
IL-10	Log concentration <i>Covariate</i> : MEQ, POD0-2 <i>Covariate</i> : Surgery (Pectus vs. Spine)	0.13 1.93 0.61	0.25 0.50 0.61	0.586 < 0.001 0.318
IL-12P70	Log concentration <i>Covariate</i> : MEQ, POD0-2	0.88 1.58	0.40 0.41	<mark>0.031</mark> <0.001
IL-13	Log concentration <i>Covariate</i> : MEQ, POD0-2	0.11 1.27	0.21 0.40	0.602 0.002
IL-1B	Log concentration <i>Covariate</i> : MEQ, POD0-2	0.84 1.75	0.36 0.43	<mark>0.023</mark> <0.001
IL-1ra	Log concentration	-0.16	2.01	0.937
IL-2	Log concentration <i>Covariate</i> : Sex (Female) <i>Covariate</i> : MEQ, POD0-2	0.78 -0.55 1.38	0.34 0.53 0.40	0.026 0.303 < 0.002
IL-4	Log concentration <i>Covariate</i> : MEQ, POD0-2	-0.18 1.04	0.25 0.35	0.485 0.004
IL-5	Log concentration <i>Covariate</i> : MEQ, POD0-2	0.17 1.51	0.27 0.41	0.535 < 0.001
IL-7	Log concentration <i>Covariate</i> : MEQ, POD0-2	0.50 1.60	0.46 0.42	0.276 <0.001
IL-8	Log concentration <i>Covariate</i> : MEQ, POD0-2 <i>Covariate</i> : Surgery (Pectus)	0.23 1.39 0.44	0.19 0.42 0.57	0.213 0.001 0.439
TNFα	Log concentration <i>Covariate</i> : MEQ, POD0-2	0.11 1.07	0.71 0.36	0.875 0.004

525 Significant p-values (<.05) bolded for covariates and cytokine associations, with those for cytokine

526 associations are marked in red text. MEQ: Morphine equivalents/kg; POD: postoperative day

527

528

25

Table 3: Regression analysis of baseline cytokine concentrations with risk (Odds) of developing chronic

531 postsurgical pain (CPSP)

			Estimate	Std	
Cytokine	Parameter with relevant covariates	Odds Ratio (95% CI)	β	Error	P -value
CCL22	Log concentration	0.20 (0.03 - 1.47)	-1.62	1.02	0.114
Fractalkine	Log concentration	0.89 (0.09 - 8.71)	-0.12	1.17	0.918
GM_CSF	Log concentration	1.35 (0.78 - 2.36)	0.30	0.28	0.285
GM_CSF	Covariate: Sex (Female vs. Male)	2.25 (1.00 - 5.09)	0.41	0.21	0.051
IFNγ	Log concentration	1.29 (0.59 - 2.81)	0.25	0.40	0.529
IFNγ	Covariate: Sex (Female vs. Male)	2.19 (0.97 - 4.94)	0.39	0.21	0.059
IL-10	Log concentration	0.78 (0.50 - 1.20)	-0.25	0.22	0.259
IL-10	Covariate: Sex (Female vs. Male)	4.27 (1.49 - 12.26)	0.73	0.27	0.007

-	-
γ	۲.
L	0

IL-10	Covariate: Surgery (pectus vs spine)	3.55 (1.15 - 10.91)	0.63	0.29	0.027
IL-12P70	Log concentration	1.07 (0.54 - 2.15)	0.07	0.35	0.840
IL-12P70	Covariate: Sex (Female vs. Male)	2.23 (0.98 - 5.07)	0.40	0.21	0.055
IL-13	Log concentration	0.79 (0.56 - 1.10)	-0.24	0.17	0.158
IL-13	Covariate: Sex (Female vs. Male)	2.35 (1.03 - 5.36)	0.43	0.21	0.042
IL-1B	Log concentration	1.29 (0.72 - 2.30)	0.25	0.30	0.396
IL-1ra	Log concentration	0.48 (0.05 - 4.65)	-0.74	1.16	0.525
IL-2	Log concentration	1.23 (0.70 - 2.17	0.21	0.29	0.468
IL-2	Covariate: Sex (Female vs. Male)	2.46 (1.07 - 5.66)	0.45	0.21	0.034
IL-4	Log concentration	0.91 (0.59 - 1.39)	-0.10	0.22	0.646
IL-4	Covariate: Sex (Female vs. Male)	2.63 (1.17 - 5.92)	0.48	0.21	0.020
IL-5	Log concentration	0.84 (0.54 - 1.30)	-0.17	0.22	0.438
IL-5	Covariate: Sex (Female vs. Male)	2.43 (1.07 - 5.55)	0.44	0.21	0.035
IL-6	Log concentration	0.82 (0.63 - 1.06	-0.20	0.13	0.132
IL-6	Covariate: Sex (Female vs. Male)	3.09 (1.16 - 8.23)	0.56	0.25	0.024
IL-7	Log concentration	1.20 (0.54 - 2.67)	0.18	0.41	0.655
IL-7	Covariate: Sex (Female vs. Male)	2.19 (0.96 - 4.99)	0.39	0.21	0.064
IL-8	Log concentration	0.68 (0.48 - 0.95)	-0.39	0.17	0.023
IL-8	Covariate: Sex (Female vs. Male)	6.13 (1.98 - 18.92)	0.91	0.29	0.002
IL-8	Covariate: Surgery (pectus vs spine)	5.53 (1.55 - 19.71)	0.86	0.32	0.009
IL-8	Covariate: MEQ POD0-2	1.20 (0.58 - 2.45)	0.18	0.37	0.627
ΤΝFα	Log concentration	0.66 (0.20 - 2.25)	-0.41	0.62	0.510
ΤΝFα	Covariate: Sex (Female vs. Male)	2.45 (1.10 - 5.48)	0.45	0.21	0.029

533 Significant p-values (<.05) bolded for covariates and cytokine associations, with those for cytokine – pain

associations marked in red text. MEQ: Morphine equivalents/kg; POD: postoperative day

535

536

537

538

539

540

Table 4. Mixed effects model (reduced model) results for significant associations of pain

outcomes and covariates with cytokine concentrations over POD0-2, adjusted for surgical

543 duration.

Dependent variable: Acute pain (Log transformed %time moderate-severe pain over POD0-2					
	Outcome: Cytokine AUC over POD0-2	Covariate: MEQ POD0-2 association with log			
Cytokine	Estimate (SE); P-value	cytokine AUC P-value			
CCL22					
Fractalkine					
GM_CSF	1.38 (.57); .02	-			
IFNγ	1.36 (.6); .03	-			
IL-10					
IL-12P70	1.17 (.58); .04	-			

27

IL-13		
IL-1B	1.25 (.59); .03	.04
IL-1ra		
IL-2		
IL-4		
IL-4 IL-5	-	.03
IL-6		
IL-7	1.65 (.7); .02	-
IL-8		
TNFα		

Dependent variable: Log Cytokine AUC over POD0-2; Association with chronic post-surgical pain (CPSP)

	Outcome: CPSP P-values for Covariate associations with Cytokine AUC					ne AUC
	Estimate (SE);		Surgical			
Cytokine	P-value	POD	duration	Sex	Race	MEQ
CCL22					.04	
Fractalkine						
GM_CSF		<.001				
IFNγ		<.001				.008
IL-10		<.001	.04	.02		
IL-12P70		<.001				
IL-13	-0.48 (0.22); .03	<.001		.005		
IL-1B		<.001				
IL-1ra		<.001				
IL-2		<.001		.01		<.001
IL-4		<.001		.004		
IL-5		<.001		.04		
IL-6	-0.57 (0.26); .03	<.001		.003		
IL-7		<.001	.004			
IL-8	-0.68 (0.24); .006	<.001		.004		
ΤΝFα		<.001	<.001			.002

544

